收藏切换
The efficacy of abrocitinib in patients with moderate to severe atopic dermatitis and its impact on skin barrier function
收藏切换
Yiheng WANG, Wenqi CHEN*
World Clinical Drug | 2026, 47(3) : 273 - 279
Less
收藏切换
World Clinical Drug | 2026, 47(3): 273-279
• Article •
The efficacy of abrocitinib in patients with moderate to severe atopic dermatitis and its impact on skin barrier function
Full
Yiheng WANG, Wenqi CHEN*
Affiliations
  • Department of Dermatology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210011, Jiangsu Province, China
Published: 2026-03-10 doi: 10.13683/j.wph.2026.03.007
Outline
收藏切换
Objective

To analyze the efficacy of abrocitinib in patients with moderate to severe atopic dermatitis(AD).

Methods

A total of 150 patients with moderate to severe AD who met the criteria in our hospital from July 2023 to January 2025 were included and divided into group A and group B by random block method, with 75 cases in each group. In addition to symptomatic treatment, group A was treated with abracitinib and group B with upadacitinib. The course of treatment for both groups was 16 weeks. After 8 and 16 weeks of treatment, the treatment responses of the two groups were observed. The following indicators were recorded: eczema area and severity index(EASI), 24-hour peak pruritus numerical rating scale(PP-NRS), dermatology life quality index(DLQI), immunoglobulin(Ig)E, eosinophil(EOS) count and skin barrier function[moisture content, sebum content, transepidermal water loss(TEWL) and the occurrence of adverse reactions.

Results

After 8 weeks of treatment, the treatment response rate, moisture content and sebum content in group A were all higher than those in group B(P<0.05), while the EASI score and TEWL were lower than those in group B(P<0.05). After 8 and 16 weeks of treatment, the PP-NRS and DLQI scores of group A were lower than those of group B(P<0.05), while there were no significant differences in serum IgE and EOS counts between the two groups(P>0.05).The incidence of gastrointestinal discomfort in group A was higher than that in group B(P<0.05), the incidence of mild to moderate acne in group B was higher than that in group A(P<0.05).

Conclusion

Abrocitinib is helpful in alleviating pruritus symptoms of moderate to severe AD at an early stage, improving the quality of life, and can repair the skin barrier function at an early stage, with a tolerable safety.

Janus kinase inhibitor  /  obrocitinib  /  upadacitinib  /  atopic dermatitis  /  skin barrier function
王奕恒, 陈文琦. 阿布昔替尼对中重度特应性皮炎患者的疗效及对皮肤屏障功能的影响研究. 世界临床药物, 2026 , 47 (3) : 273 -279 . DOI: 10.13683/j.wph.2026.03.007
Yiheng WANG, Wenqi CHEN. The efficacy of abrocitinib in patients with moderate to severe atopic dermatitis and its impact on skin barrier function[J]. World Clinical Drug, 2026 , 47 (3) : 273 -279 . DOI: 10.13683/j.wph.2026.03.007
Year 2026 volume 47 Issue 3
47
9
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2026.03.007
  • Receive Date:2025-08-28
  • Online Date:2026-11-05
  • Published:2026-03-10
Article Data
Affiliations
History
  • Received:2025-08-28
Affiliations
    Department of Dermatology, Nanjing Hospital Affiliated to Nanjing Medical University, Nanjing First Hospital, Nanjing 210011, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2026.03.007
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT